查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2083514

類風濕性關節炎治療市場：2026-2032年全球市場預測（依治療分類、分子類型、適應症、給藥途徑、患者年齡層及通路分類）

Rheumatology Therapeutics Market by Therapeutic Class, Molecule Type, Indication, Route Of Administration, Patient Age Group, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，類風濕性關節炎治療市場將成長至 558.8 億美元，複合年成長率為 6.71%。

主要市場統計數據
基準年 2025 354.5億美元
預計年份：2026年 376.8億美元
預測年份 2032 558.8億美元
複合年成長率 (%) 6.71%

風濕病治療藥物市場概覽

類風濕性關節炎藥物的治療正從單純的症狀控制朝向精準醫療發展，旨在緩解疾病類風濕性關節炎、乾癬性關節炎、中軸型脊椎關節炎、全身性紅斑性狼瘡、血管炎、痛風和骨關節炎等疾病相關的疼痛。在這一領域，傳統的合成緩解疾病抗風濕藥（DMARDs）、生物製藥、標靶合成DMARDs（如JAK抑制劑）、糖皮質激素、非類固醇消炎劑（NSAIDs）、鎮痛藥和支持療法仍發揮核心作用。

類風濕性關節炎治療的變革性變化

風濕病治療格局正經歷著從廣泛免疫抑製到通路選擇性干預的轉變。雖然TNF抑制劑在發炎性關節炎中仍發揮基礎性作用，但針對IL-6、IL-17、IL-23、B細胞、T細胞共刺激、補體、干擾素和JAK路徑的藥物正在拓展自體免疫疾病和自體發炎疾病的治療整體。

人工智慧的累積影響

人工智慧正透過臨床試驗設計、影像學、病患分層、藥物再利用、生物標記發現和藥物安全性監測，對風濕病治療日益顯著的影響。機器學習有助於從電子健康記錄、保險理賠數據、實驗室指標、超音波、磁振造影、 X光相片和患者報告結局（PRO）中識別疾病活動模式，從而支持更有針對性的受試者招募和結局測量。

類風濕性關節炎治療的主要區域趨勢

隨著專科醫療服務的擴展、生物相似藥的引入以及本地臨床研發的進展，亞太地區的戰略重要性在中國、印度、日本、韓國和澳洲日益凸顯。日本和澳洲擁有成熟的監管和保險報銷機制，而中國和印度雖然擁有龐大的患者群體，且標靶治療的應用不斷擴展，但都市區醫療資源取得仍然存在差距。在北美，類風濕性關節炎治療藥物的引入得益於高密度的專科醫生、先進的臨床試驗基礎設施、患者權益倡導團體以及保險公司積極的管理，而治療決策也越來越受到循證醫學要求、預核准和基於價值的准入討論的影響。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

東協市場正透過醫院網路的改善、公共保險覆蓋範圍的擴大、專科診所的建立以及生物相似藥供應的改善而不斷擴張，儘管新加坡、泰國、馬來西亞、印尼、越南和菲律賓在可及性方面存在顯著差異。海灣合作理事會（GCC）國家受益於對三級醫療的投資、國家醫療改革計劃、專科醫療中心生物製藥的高採用率以及日益重視長期療效、預算影響和醫療連續性的採購模式。歐盟是生物相似藥競爭、藥物安全監測、衛生技術評估以及類風濕性關節炎治療領域各國對實證醫學證據期望的全球標竿。

主要國家類風濕性關節炎治療藥物的發展趨勢

美國擁有類風濕性關節炎治療領域最有價值的市場環境，這得益於其高專科藥物使用率、生物製藥和標靶治療的廣泛普及以及與保險公司的密切談判。在加拿大，健全的指南導向醫療保健體系、省級報銷流程以及生物相似藥政策的不斷推進，共同推動了市場成長。在墨西哥和巴西，生物製藥和生物相似藥的可近性正在擴大，公共部門採購、私人保險滲透率和可負擔性等因素影響其應用程度。英國、德國、法國、義大利和西班牙仍然是歐洲的核心市場，其中德國通常支持早期上市，英國透過醫療技術評估來關注成本效益，而法國、義大利和西班牙則在臨床需求與國家和地區報銷法規之間尋求平衡。

為行業領導者提供的實用建議

產業領導者應優先考慮差異化的臨床價值，而不僅僅是提高療效。成功的策略應盡可能整合直接比較試驗的證據、持續緩解數據、類固醇減重效果、觀察進展抑制、患者報告結局、功能改善以及在合併心血管、感染疾病、腎臟、肝臟、肺部和代謝性疾病的患者群體中的安全性證據。

調查方法

本執行摘要基於二級研究框架，優先考慮檢驗的公共資訊來源，包括全球衛生組織、監管機構、同行評審文獻、臨床試驗註冊庫、治療指南、藥物安全監測資料庫和衛生技術評估 (HTA) 出版物。疾病負擔、治療藥物類別的演變、可近性趨勢、安全性考慮以及區域應用趨勢均採用多方面證據進行評估，而非僅依賴單一資訊來源的解讀。

結論

類風濕性關節炎治療市場正進入一個競爭更加激烈、以循證醫學為導向的階段，其特點是靶向作用機制、生物類似藥的擴張、人工智慧驅動的決策支持以及對可衡量患者主導日益成長的需求。當臨床差異化與支付方的財務能力、醫生的信心、安全性透明度和可操作的醫療服務取得途徑相契合時，將會出現最大的機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：類風濕性關節炎藥物市場：依治療分類

  • 傳統DMARDs
    • 羥氯喹
    • 來氟米德
    • 胺基甲基葉酸
    • 柳氮磺胺吡啶
  • IL-6抑制劑
  • JAK抑制劑
  • TNF抑制劑

第8章：類風濕性關節炎治療市場：依分子類型分類

  • 生物製劑
  • 生物相似藥
  • 低分子化合物

第9章：類風濕性關節炎治療市場：依適應症分類

  • 僵直性脊椎炎
  • 痛風
  • 乾癬性關節炎
  • 類風濕性關節炎
  • 全身性紅斑性狼瘡

第10章：類風濕性關節炎治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第11章：類風濕性關節炎治療市場：依患者年齡層分類

  • 成人
  • 兒童

第12章：類風濕性關節炎治療市場：依通路分類

  • 離線
  • 線上

第13章：類風濕性關節炎治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：類風濕性關節炎治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：類風濕性關節炎治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AbbVie Inc.
  • Aclaris Therapeutics, Inc.
  • Almirall, SA
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bio-Thera Solutions, Ltd.
  • Bristol-Myers Squibb Company
  • Chemomab Therapeutics Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Galapagos NV
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • Johnson & Johnson services Inc.
  • Mallinckrodt Pharmaceuticals plc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Taisho Pharmaceutical Holdings
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
Product Code: MRR-437896AA372B

The Rheumatology Therapeutics Market is projected to grow by USD 55.88 billion at a CAGR of 6.71% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 35.45 billion
Estimated Year [2026] USD 37.68 billion
Forecast Year [2032] USD 55.88 billion
CAGR (%) 6.71%

Rheumatology Therapeutics Market Introduction

Rheumatology therapeutics is advancing from symptom control toward precision disease modification across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus, vasculitis, gout, and osteoarthritis pain management. The category remains anchored by conventional synthetic disease-modifying antirheumatic drugs, biologics, targeted synthetic DMARDs such as JAK inhibitors, corticosteroids, NSAIDs, analgesics, and supportive care.

The demand base is clinically significant and well documented. The World Health Organization estimates that rheumatoid arthritis affected about 18 million people globally in 2019, while osteoarthritis affected approximately 528 million people. Aging populations, earlier diagnosis, treat-to-target strategies, expanding specialty access, and the growing recognition of autoimmune and musculoskeletal disease burden continue to sustain demand for effective, safe, and reimbursable rheumatology drugs.

Transformative Shifts in Rheumatology Therapeutics

The rheumatology therapeutics landscape is being reshaped by the shift from broad immunosuppression to pathway-selective intervention. TNF inhibitors remain foundational in inflammatory arthritis, while IL-6, IL-17, IL-23, B-cell, T-cell costimulation, complement, interferon, and JAK pathway agents are expanding treatment choices across autoimmune and autoinflammatory diseases.

Biosimilars are transforming pricing, procurement, and access, especially for high-volume biologics used in rheumatoid arthritis, psoriasis-related arthritis, and spondyloarthritis. At the same time, safety surveillance, boxed warnings for some targeted therapies, infection-risk management, and payer-driven step therapy are making real-world evidence, pharmacovigilance, adherence support, and differentiated outcomes essential for commercial success.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly influencing rheumatology therapeutics through trial design, imaging interpretation, patient stratification, drug repurposing, biomarker discovery, and pharmacovigilance. Machine learning can help identify disease activity patterns from electronic health records, claims, laboratory markers, ultrasound, MRI, radiographs, and patient-reported outcomes, supporting more targeted enrollment and outcome measurement.

The cumulative impact is expected to be greatest where AI reduces diagnostic delay, predicts treatment response, detects safety signals, and improves adherence monitoring. However, clinical validation, algorithm transparency, representative datasets, privacy protection, and regulatory-grade evidence remain critical because rheumatic diseases vary by ethnicity, comorbidity burden, disease duration, socioeconomic access, and prior treatment exposure.

Key Regional Insights for Rheumatology Therapeutics

Asia-Pacific is gaining strategic importance as China, India, Japan, South Korea, and Australia expand specialty care, biosimilar adoption, and local clinical development. Japan and Australia have mature regulatory and reimbursement pathways, while China and India provide large patient pools and growing use of targeted therapies, although access remains uneven across urban and rural health systems. In North America, rheumatology therapeutics adoption is supported by specialist density, advanced clinical trial infrastructure, patient advocacy, and active payer management, with treatment decisions increasingly shaped by evidence requirements, prior authorization, and value-based access discussions.

Europe remains a major evidence-generation and biosimilar adoption center, strengthened by centralized and national regulatory processes, health technology assessment frameworks, and guideline-led treat-to-target care. Latin America is improving diagnosis and biologic availability in countries with expanding public and private specialty networks, but affordability and procurement consistency remain key constraints. The Middle East, particularly tertiary-care-focused health systems, is advancing access to biologics and targeted synthetic therapies, while Africa continues to face wider gaps in specialist availability, diagnostics, cold-chain logistics, and reimbursement, making scalable access models essential for long-term rheumatology care.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are expanding through improving hospital networks, public insurance coverage, specialty clinic development, and biosimilar availability, though access differs materially between Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. GCC countries benefit from investment in tertiary care, national health transformation programs, high biologic uptake in specialist centers, and procurement models that increasingly evaluate long-term outcomes, budget impact, and treatment continuity. The European Union is a global benchmark for biosimilar competition, pharmacovigilance, health technology assessment, and cross-country evidence expectations in rheumatology therapeutics.

BRICS economies combine large autoimmune and musculoskeletal disease burdens with growing domestic manufacturing, biosimilar development, and clinical trial capacity, although reimbursement depth and specialty access vary significantly. G7 markets remain central to premium innovation, regulatory influence, guideline adoption, and launch sequencing, supported by mature rheumatology networks and established safety monitoring. NATO members overlap substantially with advanced regulatory systems, resilient pharmaceutical supply-chain priorities, and coordinated public health preparedness, which can influence procurement security for immunology and rheumatology medicines.

Key Country Insights in Rheumatology Therapeutics

The United States remains the leading high-value environment for rheumatology therapeutics due to high specialty drug utilization, broad biologic and targeted therapy availability, and intensive payer negotiation. Canada combines strong guideline-based care with provincial reimbursement processes and growing biosimilar policy adoption. Mexico and Brazil are expanding biologic and biosimilar access, although public-sector procurement, private insurance penetration, and affordability shape uptake. The United Kingdom, Germany, France, Italy, and Spain remain core European markets, with Germany often supporting early launch access, the United Kingdom emphasizing cost-effectiveness through health technology assessment, and France, Italy, and Spain balancing clinical need with national and regional reimbursement controls.

Russia continues to develop domestic biologic and biosimilar capacity despite geopolitical and supply-chain pressures. China is scaling local innovation, centralized procurement mechanisms, regulatory modernization, and specialty access, while India's market is driven by affordability, branded generics, biosimilars, and high out-of-pocket sensitivity. Japan has sophisticated regulatory standards, an aging population, and strong clinical guideline adoption. Australia combines high clinical standards with structured reimbursement assessment, and South Korea serves both as an advanced treatment market and a major biosimilar manufacturing and development hub, supported by strong biopharmaceutical infrastructure.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize differentiated clinical value, not only incremental efficacy. Successful strategies should integrate head-to-head evidence where feasible, durable remission data, steroid-sparing outcomes, radiographic progression control, patient-reported outcomes, functional improvement, and safety evidence in populations with cardiovascular, infectious, renal, hepatic, pulmonary, and metabolic comorbidities.

Commercial teams should prepare for biosimilar-driven price pressure by strengthening lifecycle management, companion diagnostics, patient support, real-world evidence generation, clinician education, and access partnerships. R&D leaders should invest in biomarkers, adaptive trials, decentralized monitoring, and AI-enabled response prediction while maintaining rigorous validation, regulatory alignment, and post-market surveillance across diverse patient populations.

Research Methodology

This executive summary is built from a secondary research framework that prioritizes verified public sources, including global health agencies, regulatory authorities, peer-reviewed literature, clinical trial registries, treatment guidelines, pharmacovigilance databases, and health technology assessment publications. Disease burden, therapeutic class evolution, access trends, safety considerations, and regional adoption dynamics were assessed using triangulated evidence rather than single-source interpretation.

The methodology emphasizes market relevance for decision-makers by combining epidemiology, product class analysis, regulatory context, reimbursement dynamics, pipeline direction, prescribing patterns, and real-world implementation factors. Insights are synthesized to support strategic planning across manufacturers, investors, distributors, healthcare providers, payers, and policy stakeholders in rheumatology therapeutics without relying on market sizing, market share, or forecasting assumptions.

Conclusion

Rheumatology therapeutics is entering a more competitive and evidence-driven phase, defined by targeted mechanisms, biosimilar expansion, AI-enabled decision support, and greater demand for measurable patient outcomes. The strongest opportunities will emerge where clinical differentiation aligns with payer affordability, physician confidence, safety transparency, and practical access.

Organizations that combine scientific innovation with real-world evidence, pharmacovigilance strength, patient-centered support, and region-specific access models will be best positioned to advance care. As autoimmune and musculoskeletal disease burdens rise globally, the rheumatology therapeutics landscape will reward therapies that improve remission, function, adherence, treatment persistence, and long-term quality of life.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Rheumatology Therapeutics Market, by Therapeutic Class

  • 7.1. Conventional DMARDs
    • 7.1.1. Hydroxychloroquine
    • 7.1.2. Leflunomide
    • 7.1.3. Methotrexate
    • 7.1.4. Sulfasalazine
  • 7.2. IL-6 Inhibitors
  • 7.3. JAK Inhibitors
  • 7.4. TNF Inhibitors

8. Rheumatology Therapeutics Market, by Molecule Type

  • 8.1. Biologics
  • 8.2. Biosimilars
  • 8.3. Small Molecules

9. Rheumatology Therapeutics Market, by Indication

  • 9.1. Ankylosing Spondylitis
  • 9.2. Gout
  • 9.3. Psoriatic Arthritis
  • 9.4. Rheumatoid Arthritis
  • 9.5. Systemic Lupus Erythematosus

10. Rheumatology Therapeutics Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Rheumatology Therapeutics Market, by Patient Age Group

  • 11.1. Adult
  • 11.2. Pediatric

12. Rheumatology Therapeutics Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Rheumatology Therapeutics Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Rheumatology Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Rheumatology Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc.
  • 17.2. Aclaris Therapeutics, Inc.
  • 17.3. Almirall, S.A.
  • 17.4. Amgen Inc.
  • 17.5. Astellas Pharma Inc.
  • 17.6. AstraZeneca PLC
  • 17.7. Bio-Thera Solutions, Ltd.
  • 17.8. Bristol-Myers Squibb Company
  • 17.9. Chemomab Therapeutics Ltd.
  • 17.10. Dr. Reddy's Laboratories Ltd.
  • 17.11. Eli Lilly and Company
  • 17.12. F. Hoffmann-La Roche Ltd.
  • 17.13. Galapagos NV
  • 17.14. Gilead Sciences, Inc.
  • 17.15. GlaxoSmithKline plc
  • 17.16. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 17.17. Johnson & Johnson services Inc.
  • 17.18. Mallinckrodt Pharmaceuticals plc
  • 17.19. Novartis AG
  • 17.20. Pfizer Inc.
  • 17.21. Sanofi S.A.
  • 17.22. Sun Pharmaceutical Industries Ltd.
  • 17.23. Taisho Pharmaceutical Holdings
  • 17.24. Takeda Pharmaceutical Company Limited
  • 17.25. Teva Pharmaceutical Industries Ltd.
  • 17.26. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONVENTIONAL DMARDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONVENTIONAL DMARDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONVENTIONAL DMARDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HYDROXYCHLOROQUINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HYDROXYCHLOROQUINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HYDROXYCHLOROQUINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LEFLUNOMIDE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LEFLUNOMIDE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LEFLUNOMIDE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL METHOTREXATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL METHOTREXATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL METHOTREXATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SULFASALAZINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SULFASALAZINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SULFASALAZINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IL-6 INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IL-6 INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IL-6 INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL JAK INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL JAK INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL JAK INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TNF INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TNF INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TNF INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOSIMILARS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOSIMILARS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOSIMILARS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL GOUT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL GOUT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL GOUT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PSORIATIC ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 138. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 141. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GCC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 160. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 161. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 162. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 165. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. G7 RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 170. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 172. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 173. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. NATO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 179. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 186. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 187. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 195. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 197. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 198. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 199. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 201. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 203. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 219. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 221. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 222. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 226. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 227. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 230. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 232. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 233. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 234. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 235. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 243. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 245. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 247. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 250. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 251. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 253. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 255. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 266. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 267. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 269. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 270. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 271. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 272. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 273. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 274. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 275. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 277. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 278. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 279. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 282. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 283. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 285. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 287. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 290. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY CONVENTIONAL DMARDS, 2018-2032 (USD MILLION)
  • TABLE 291. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 293. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 294. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 295. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)